Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy

Bibliography

• Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2: REVIEWS3005: published online 9 March 2001, doi:10.1186/gb-2001-2-3-reviews3005
   PubMed Web of Science ®Google Scholar
• Olsen SK, Garbi M, Zampieri N, Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 2003;278:34226-36
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20:563-9
   PubMed Web of Science ®Google Scholar
• Berger W, Setinek U, Mohr T, Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 1999;83:415-23
   PubMed Web of Science ®Google Scholar
• Aigner A, Butscheid M, Kunkel P, An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 2001;92:510-17
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Plotnikov AN, Ibrahimi OA, Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR Binding and dimerization. Molecular Cell 2000;6:743-50
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49
   PubMed Web of Science ®Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. J Biol Chem 2006;281:15694-700
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Dikic I, Sorokin A, Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 1996;16:977-89
   PubMed Web of Science ®Google Scholar
• Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 2008;99:1319-25
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Honegger AM, Rotin D, A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma1. Mol Cell Biol 1991;11:5068-78
   PubMed Web of Science ®Google Scholar
• Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci 1999;4:D165-77
   PubMedGoogle Scholar
• Dikic I, Giordano S. Negative receptor signalling. Curr Opin Cell Biol 2003;15:128-35
   PubMed Web of Science ®Google Scholar
• Hacohen N, Kramer S, Sutherland D, sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998;92:253-63
   PubMed Web of Science ®Google Scholar
• de Maximy AA, Nakatake Y, Moncada S, Cloning and expression pattern of a mouse homologue of Drosophila sprouty in the mouse embryo. Mech Dev 1999;81:213-16
   PubMed Web of Science ®Google Scholar
• Mason JM, Morrison DJ, Basson MA, Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 2006;16:45-54
   PubMed Web of Science ®Google Scholar
• Minowada G, Jarvis LA, Chi CL, Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 1999;126:4465-75
   PubMed Web of Science ®Google Scholar
• Chambers D, Mason I. Expression of sprouty2 during early development of the chick embryo is coincident with known sites of FGF signalling. Mech Dev 2000;91:361-4
   PubMed Web of Science ®Google Scholar
• Ozaki K, Kadomoto R, Asato K, ERK pathway positively regulates the expression of Sprouty genes. Biochem Biophys Res Commun 2001;285:1084-8
   PubMed Web of Science ®Google Scholar
• Mayer CE, Haigl B, Jantscher F, Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cell Mol Life Sci 2010;67:3299-311
   PubMed Web of Science ®Google Scholar
• Edwin F, Anderson K, Ying C, Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol 2009;76:679-91
   PubMed Web of Science ®Google Scholar
• Kovalenko D, Yang X, Nadeau RJ, Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem 2003;278:14087-91
   PubMed Web of Science ®Google Scholar
• Huang F, Kirkpatrick D, Jiang X, Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 2006;21:737-48
   PubMed Web of Science ®Google Scholar
• Wong A, Lamothe B, Lee A, FRS2alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci USA 2002;99:6684-9
   PubMed Web of Science ®Google Scholar
• Cho JY, Guo C, Torello M, Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 2004;101:609-14
   PubMed Web of Science ®Google Scholar
• Haugsten EM, Malecki J, Bjorklund SM, Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. Mol Biol Cell 2008;19:3390-403
   PubMed Web of Science ®Google Scholar
• Francavilla C, Cattaneo P, Berezin V, The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. J Cell Biol 2009;187:1101-16
   PubMed Web of Science ®Google Scholar
• Cavallaro U, Niedermeyer J, Fuxa M, N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001;3:650-7
   PubMed Web of Science ®Google Scholar
• Williams EJ, Furness J, Walsh FS, Activation of the FGF receptor underlies neurite outgrowth stimulated by L1, N-CAM, and N-cadherin. Neuron 1994;13:583-94
   PubMed Web of Science ®Google Scholar
• Lehembre F, Yilmaz M, Wicki A, NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J 2008;27:2603-15
   PubMed Web of Science ®Google Scholar
• Chambers SM, Fasano CA, Papapetrou EP, Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27:275-80
   PubMed Web of Science ®Google Scholar
• Rathjen J, Lake JA, Bettess MD, Formation of a primitive ectoderm like cell population, EPL cells, from ES cells in response to biologically derived factors. J Cell Sci 1999;112:601-12
   PubMed Web of Science ®Google Scholar
• Pelton TA, Sharma S, Schulz TC, Transient pluripotent cell populations during primitive ectoderm formation: correlation of in vivo and in vitro pluripotent cell development. J Cell Sci 2002;115:329-39
   PubMed Web of Science ®Google Scholar
• Pearson S, Sroczynska P, Lacaud G, The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF. Development 2008;135:1525-35
   PubMed Web of Science ®Google Scholar
• Chamorro MN, Schwartz DR, Vonica A, FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005;24:73-84
   PubMed Web of Science ®Google Scholar
• Hendrix ND, Wu R, Kuick R, Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006;66:1354-62
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. Int J Mol Med 2006;17:529-32
   PubMed Web of Science ®Google Scholar
• Shimokawa T, Furukawa Y, Sakai M, Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res 2003;63:6116-20
   PubMed Web of Science ®Google Scholar
• Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 2010;106:1798-806
   PubMed Web of Science ®Google Scholar
• Meyers EN, Lewandoski M, Martin GR. An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat Genet 1998;18:136-41
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29
   PubMed Web of Science ®Google Scholar
• Colvin, JS, White AC, Pratt SJ, Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development 2001;128:2095-106
   PubMed Web of Science ®Google Scholar
• Sekine K, Ohuchi H, Fujiwara M, Fgf10 is essential for limb and lung formation. Nat Genet 1999;21:138-41
   PubMed Web of Science ®Google Scholar
• Itoh N. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 2007;30:1819-25
   PubMed Web of Science ®Google Scholar
• Tekin M, Ozturkmen Akay H, Fitoz S, Homozygous FGF3 mutations result in congenital deafness with inner ear agenesis, microtia, and microdontia. Clin Genet 2008;73:554-65
   PubMed Web of Science ®Google Scholar
• Wiedemann HR. Salivary gland disorders and heredity. Am J Med Genet 1997;68:222-4
   PubMed Web of Science ®Google Scholar
• van der Walt JM, Noureddine MA, Kittappa R, Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet 2004;74:1121-7
   PubMed Web of Science ®Google Scholar
• Wang G, van der Walt JM, Mayhew G, Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 2008;82:283-9
   PubMed Web of Science ®Google Scholar
• Shimada T, Mizutani S, Muto T, Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5
   PubMed Web of Science ®Google Scholar
• Kannan K, Givol D. FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models. IUBMB Life 2000;49:197-205
   PubMed Web of Science ®Google Scholar
• Tavormina PL, Bellus GA, Webster MK, A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 1999;64:722-31
   PubMed Web of Science ®Google Scholar
• Webster MK, Donoghue DJ. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997;13:178-82
   PubMed Web of Science ®Google Scholar
• Braun S, auf dem Keller U, Steiling H, Fibroblast growth factors in epithelial repair and cytoprotection. Philos Trans R Soc Lond B Biol Sci 2004;359:753-7
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Healing the epithelium: solving the problem from two sides. J Gastroenterol 1997;32:122-6
   PubMed Web of Science ®Google Scholar
• Abuharbeid S, Czubayko F, Aigner A. The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol 2006;38:1463-8
   PubMed Web of Science ®Google Scholar
• Beer HD, Bittner M, Niklaus G, The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair. Oncogene 2005;24:5269-77
   PubMed Web of Science ®Google Scholar
• Su S-C, Mendoza EA, Kwak H-I, Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in wound healing. Am J Physiol Cell Physiol 2008;295:C1215-29
   PubMed Web of Science ®Google Scholar
• Antoine M, Wirz W, Tag CG, Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors 2005;23:87-95
   PubMed Web of Science ®Google Scholar
• Nugent M, A Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:115-20
   PubMed Web of Science ®Google Scholar
• Antoine M, Wirz W, Tag CG, Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem Biophys Res Commun 2006;346:224-33
   PubMed Web of Science ®Google Scholar
• Deroanne CF, Hajitou A, Calberg Bacq CM, Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997;57:5590-7
   PubMed Web of Science ®Google Scholar
• Barrientos S, Stojadinovic O, Golinko MS, Growth factors and cytokines in wound healing. Wound Repair Regen 2008;16:585-601
   PubMed Web of Science ®Google Scholar
• Grose R, Werner S. Wound-healing studies in transgenic and knockout mice. Mol Biotechnol 2004;28:147-66
   PubMed Web of Science ®Google Scholar
• Orr-Urtreger A, Bedford MT, Burakova T, Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 1993;158:475-86
   PubMed Web of Science ®Google Scholar
• Lonai P. Epithelial mesenchymal interactions, the ECM and limb development. J Anat 2003;202:43-50
   PubMed Web of Science ®Google Scholar
• Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004;91:69-136
   PubMed Web of Science ®Google Scholar
• Veltmaat JM, Mailleux AA, Thiery JP, Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation. Differentiation 2003;71:1-17
   PubMed Web of Science ®Google Scholar
• Tickle C, Munsterberg A. Vertebrate limb development-the early stages in chick and mouse. Curr Opin Genet Dev 2001;11:476-81
   PubMed Web of Science ®Google Scholar
• Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 2010;342:1-11
   PubMed Web of Science ®Google Scholar
• Sinha J, Chen F, Miloh T, beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. Am J Physiol Gastrointest Liver Physiol 2008;295:G996-1003
   PubMed Web of Science ®Google Scholar
• Tomlinson E, Fu L, John L, Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143:1741-7
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Miyake A, Nakagawa Y, Fgf19 is required for zebrafish lens and retina development. Dev Biol 2008;313:752-66
   PubMed Web of Science ®Google Scholar
• Vincentz JW, McWhirter JR, Murre C, Fgf15 is required for proper morphogenesis of the mouse cardiac outflow tract. Genesis 2005;41:192-201
   PubMed Web of Science ®Google Scholar
• Inagaki T, Choi M, Moschetta A, Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-25
   PubMed Web of Science ®Google Scholar
• Yu C, Wang F, Kan M, Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000;275:15482-9
   PubMed Web of Science ®Google Scholar
• Badman MK, Koester A, Flier JS, Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009;150:4931-40
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-535
   PubMed Web of Science ®Google Scholar
• Consortium A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8
   PubMed Web of Science ®Google Scholar
• Shimada T, Hasegawa H, Yamazaki Y, FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Haugsten EM, Wiedlocha A, Olsnes S, Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010;8:1439-52
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R, Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8
   PubMed Web of Science ®Google Scholar
• Taylor JG VI, Cheuk AT, Tsang PS, Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009;119:3395-407
   PubMed Web of Science ®Google Scholar
• Kunii K, Davis L, Gorenstein J, FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-8
   PubMed Web of Science ®Google Scholar
• Nakazawa K, Yashiro M, Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res 2003;63:8848-52
   PubMed Web of Science ®Google Scholar
• Takeda M, Arao T, Yokote H, AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007;13:3051-7
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yashiro M, Matsuoka T, A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology 2006;131:1530-41
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2: 62ra93
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Facon T, Daviet A, 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999;59:4546-50
   PubMed Web of Science ®Google Scholar
• Bange J, Prechtl D, Cheburkin Y, Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Cancer Res 2002;62:840-7
   PubMed Web of Science ®Google Scholar
• Spinola M, Leoni VP, Tanuma J, FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005;14:415-19
   PubMed Web of Science ®Google Scholar
• Streit S, Bange J, Fichtner A, Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004;111:213-17
   PubMed Web of Science ®Google Scholar
• Streit S, Mestel DS, Schmidt M, FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006;94:1879-86
   PubMed Web of Science ®Google Scholar
• Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004;10:6169-78
   PubMed Web of Science ®Google Scholar
• Thussbas C, Nahrig J, Streit S, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006;24:3747-55
   PubMedGoogle Scholar
• Roidl A, Berger H-J, Kumar S, Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009;15:2058-66
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Brennan JP, Slavin JL, Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66:11271-8
   PubMed Web of Science ®Google Scholar
• Matsubara A, Kan M, Feng S, Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 1998;58:1509-14
   PubMed Web of Science ®Google Scholar
• Ricol D, Cappellen D, El Marjou A, Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999;18:7234-43
   PubMed Web of Science ®Google Scholar
• Jang JH. Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis. Oncogene 2005;24:945-8
   PubMed Web of Science ®Google Scholar
• Sonvilla G, Allerstorfer S, Heinzle C, Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer 2010;102:1145-56
   PubMed Web of Science ®Google Scholar
• Smith K, Fox SB, Whitehouse R, Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol 1999;10:707-13
   PubMed Web of Science ®Google Scholar
• Okada-Ban M, Moens G, Thiery JP, Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells. Oncogene 1999;18:6719-24
   PubMed Web of Science ®Google Scholar
• Hanada K-I, Perry-Lalley DM, Ohnmacht GA, Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res 2001;61:5511-16
   PubMed Web of Science ®Google Scholar
• Allerstorfer S, Sonvilla G, Fischer H, FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene 2008;27:4180-90
   PubMed Web of Science ®Google Scholar
• Jensen RL, Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998;49:189-95; discussion 196
   PubMed Web of Science ®Google Scholar
• Todo T, Kondo T, Kirino T, Expression and growth stimulatory effect of fibroblast growth factor 9 in human brain tumors. Neurosurgery 1998;43:337-46
   PubMed Web of Science ®Google Scholar
• Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-24
   PubMed Web of Science ®Google Scholar
• Metzner T, Held G, Bedeir A, Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol 2011, in revision
   Google Scholar
• Halaban R, Kwon BS, Ghosh S, bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988;3:177-86
   PubMedGoogle Scholar
• Fischer H, Taylor N, Allerstorfer S, Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008;7:3408-19
   PubMed Web of Science ®Google Scholar
• Sonvilla G, Allerstorfer S, Stattner S, FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis 2008;29:15-24
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Pai R, Ferrando RE, Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27:85-97
   PubMed Web of Science ®Google Scholar
• Uematsu S, Higashi T, Nouso K, Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:583-8
   PubMed Web of Science ®Google Scholar
• Hu MC, Qiu WR, Wang YP, FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. Mol Cell Biol 1998;18:6063-74
   PubMed Web of Science ®Google Scholar
• Hu Z, Evarts RP, Fujio K, Expression of transforming growth factor alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis. Carcinogenesis 1996;17:931-8
   PubMed Web of Science ®Google Scholar
• Kin M, Sata M, Ueno T, Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 1997;27:677-87
   PubMed Web of Science ®Google Scholar
• Gauglhofer C, Sagmeister S, Schrottmaier W, Upregulation of fibroblast growth factor 8-subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 2011;53:854-64
   Google Scholar
• Sutterluty H, Mayer CE, Setinek U, Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res 2007;5:509-20
   PubMed Web of Science ®Google Scholar
• Shaw AT, Meissner A, Dowdle JA, Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 2007;21:694-707
   PubMed Web of Science ®Google Scholar
• Minowada G, Miller YE. Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis. Am J Respir Cell Mol Biol 2009;40:31-7
   PubMed Web of Science ®Google Scholar
• Tennis MA, Van Scoyk MM, Freeman SV, Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res 8:833-43
   PubMed Web of Science ®Google Scholar
• Kwabi-Addo B, Wang J, Erdem H, The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004;64:4728-35
   PubMed Web of Science ®Google Scholar
• Wang J, Thompson B, Ren C, Sprouty 4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate 2006;66:613-24
   PubMed Web of Science ®Google Scholar
• McKie AB, Douglas DA, Olijslagers S, Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005;24:2166-74
   PubMed Web of Science ®Google Scholar
• Lo TL, Yusoff P, Fong CW, The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004;64:6127-36
   PubMed Web of Science ®Google Scholar
• Fong CW, Chua MS, McKie AB, Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006;66:2048-58
   PubMed Web of Science ®Google Scholar
• Lee SA, Ho C, Roy R, Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology 2008;47:1200-10
   PubMed Web of Science ®Google Scholar
• Frank MJ, Dawson DW, Bensinger SJ, Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood 2009;113:2478-87
   PubMed Web of Science ®Google Scholar
• Zisman-Rozen S, Fink D, Ben-Izhak O, Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas. Oncogene 2007;26:6093-8
   PubMed Web of Science ®Google Scholar
• Pardo, OE, Wellbrock C, Khanzada UK, FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCϵ, B-Raf and S6K2. EMBO J 2006;25:3078-88
   PubMed Web of Science ®Google Scholar
• Pardo OE, Arcaro A, Salerno G, Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 2002;277:12040-6
   PubMed Web of Science ®Google Scholar
• Motomura K, Hagiwara A, Komi-Kuramochi A, An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection. Biochimica et Biophysica Acta (BBA) - General Subjects 2008;1780:1432-40
   PubMed Web of Science ®Google Scholar
• Pardo OE, Lesay A, Arcaro A, Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol 2003;23:7600-10
   PubMed Web of Science ®Google Scholar
• Kono SA, Marshall ME, Ware KE, The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 2009;12:95-102
   PubMed Web of Science ®Google Scholar
• Liu, B, Fang M, Lu Y, Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 2001;20:1913-22
   PubMed Web of Science ®Google Scholar
• Pardo OE, Latigo J, Jeffery RE, The Fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009;69:8645-51
   PubMed Web of Science ®Google Scholar
• Brünner-Kubath C, Shabbir W, Saferding V, The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2010:1-14
   Web of Science ®Google Scholar
• Xian W, Schwertfeger KL, Vargo-Gogola T, Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 2005;171:663-73
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Marchionni L, Huang Z, Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 2008;27:7180-91
   PubMed Web of Science ®Google Scholar
• Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMS in cancer. Nat Rev Cancer 2004;4:118-32
   PubMed Web of Science ®Google Scholar
• Wang J, Yu W, Cai Y, Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008;10:847-56
   PubMed Web of Science ®Google Scholar
• da Costa Andrade VC, Parise O Jr, Hors CP, The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007;82:53-7
   PubMed Web of Science ®Google Scholar
• Spinola M, Leoni V, Pignatiello C, Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005;23:7307-11
   PubMed Web of Science ®Google Scholar
• Monsonego-Ornan E, Adar R, Feferman T, The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 2000;20:516-22
   PubMed Web of Science ®Google Scholar
• Cymer F, Schneider D. Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cell Adh Migr 2010;4:299-312
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
   PubMed Web of Science ®Google Scholar
• Mignatti P, Rifkin DB. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? J Cell Biochem 1991;47:201-7
   PubMed Web of Science ®Google Scholar
• Compagni A, Wilgenbus P, Impagnatiello MA, Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000;60:7163-9
   PubMed Web of Science ®Google Scholar
• Ria R, Reale A, Castrovilli A, Angiogenesis and progression in human melanoma. Dermatol Res Pract 2010;2010:185687
   PubMedGoogle Scholar
• Huang YQ, Li JJ, Nicolaides A, Increased expression of fibroblast growth factors (FGFs) and their receptor by protamine and suramin on Kaposi's sarcoma-derived cells. Anticancer Res 1993;13:887-90
   PubMed Web of Science ®Google Scholar
• Li JJ, Huang YQ, Moscatelli D, Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived cells. Cancer 1993;72:2253-9
   PubMed Web of Science ®Google Scholar
• Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010;125:105-17
   PubMed Web of Science ®Google Scholar
• Powers, CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97
   PubMed Web of Science ®Google Scholar
• Nicholes K, Guillet S, Tomlinson E, A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295-307
   PubMed Web of Science ®Google Scholar
• Qing J, Du X, Chen Y, Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009;119:1216-29
   PubMed Web of Science ®Google Scholar
• Ueno H, Gunn M, Dell K, A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J Biol Chem 1992;267:1470-6
   PubMed Web of Science ®Google Scholar
• Paterson JL, Li Z, Wen XY, Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004;124:595-603
   PubMed Web of Science ®Google Scholar
• Xin X, Abrams TJ, Hollenbach PW, CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006;12:4908-15
   PubMed Web of Science ®Google Scholar
• Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 2008;33:233-7
   PubMed Web of Science ®Google Scholar
• Novartis. A dose escalation study in adult patients with advanced solid malignancies. ClinicalTrials.gov, NCT01004224. Available from: http://clinicaltrials.gov/ct2/show/NCT01004224
   Google Scholar
• AstraZeneca. Study is designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced tumours. ClinicalTrials.gov, NCT00979134. Available from: http://clinicaltrials.gov/ct2/show/NCT00979134
   Google Scholar
• AstraZeneca. Safety and efficacy of AZD4547 in combination with exemestane versus exemestane alone in ER+ breast cancer patients. ClinicalTrials.gov, NCT01202591. Available from: http://clinicaltrials.gov/ct2/show/NCT01202591
   Google Scholar
• Shimada T, Kakitani M, Yamazaki Y, Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8
   PubMed Web of Science ®Google Scholar
• Huang X, Yang C, Jin C, Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog 2009;48:553-62
   PubMed Web of Science ®Google Scholar
• Sarker D, Molife R, Evans TR, A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008;14:2075-81
   PubMed Web of Science ®Google Scholar
• Sun HD, Malabunga M, Tonra JR, Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab 2007;292:E964-76
   PubMed Web of Science ®Google Scholar
• Ezzat S, Zheng L, Yu S, A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. Biochem Biophys Res Commun 2001;287:60-5
   PubMed Web of Science ®Google Scholar
• Tolcher A, Papadopulos K, Patniak A, Preliminary results of a dose escalation study of the fibroblast growth factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies. Eur J Cancer 2010;8:121
   Google Scholar
• Ezzat S, Huang P, Dackiw A, Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 2005;11:1336-41
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med 2005;26:314-22
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart AK, Rom E, The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107:4039-46
   PubMed Web of Science ®Google Scholar
• Trudel S, Ely S, Farooqi Y, Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004;103:3521-8
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Wei E, CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941-8
   PubMed Web of Science ®Google Scholar
• Feng YH, Tsao CJ, Wu CL, Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Sci 101:2033-8
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24
   PubMed Web of Science ®Google Scholar
• Weinstein M, Xu X, Ohyama K, FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 1998;125:3615-23
   PubMed Web of Science ®Google Scholar
• Hadari Y, Schlessinger J, FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Invest 2009;119:1077-9
   PubMed Web of Science ®Google Scholar
• Davies H, Hunter C, Smith R, Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75
   PubMed Web of Science ®Google Scholar
• Rand V, Huang J, Stockwell T, Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 2005;102:14344-9
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8
   PubMed Web of Science ®Google Scholar
• Gartside MG, Chen H, Ibrahimi OA, Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 2009;7:41-54
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen TH, Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008;105:8713-17
   PubMed Web of Science ®Google Scholar
• Byron SA, Gartside MG, Wellens CL, FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010;117:125-9
   PubMed Web of Science ®Google Scholar
• Pollock PM, Gartside MG, Dejeza LC, Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62
   PubMed Web of Science ®Google Scholar
• Hernandez S, Lopez-Knowles E, Lloreta J, Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664-71
   PubMed Web of Science ®Google Scholar
• Tomlinson DC, Baldo O, Harnden P, FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-8
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Montironi R, Zwarthoff EC, Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002;198:245-51
   PubMed Web of Science ®Google Scholar
• Zieger K, Dyrskjot L, Wiuf C, Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005;11:7709-19
   PubMed Web of Science ®Google Scholar
• Hernandez S, de Muga S, Agell L, FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol 2009;22:848-56
   PubMedGoogle Scholar
• Cappellen D, De Oliveira C, Ricol D, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20
   PubMed Web of Science ®Google Scholar
• Claudio JO, Zhan F, Zhuang L, Expression and mutation status of candidate kinases in multiple myeloma. Leukemia 2007;21:1124-7
   PubMed Web of Science ®Google Scholar
• Intini D, Baldini L, Fabris S, Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001;114:362-4
   PubMed Web of Science ®Google Scholar
• Onwuazor ON, Wen XY, Wang DY, Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003;102:772-3
   PubMed Web of Science ®Google Scholar
• Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008;4:71-83
   PubMed Web of Science ®Google Scholar
• Goriely A, Hansen RM, Taylor IB, Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 2009;41:1247-52
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12
   PubMed Web of Science ®Google Scholar
• Sung MT, Zhang S, Lopez-Beltran A, Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. Histopathology 2009;55:161-73
   PubMed Web of Science ®Google Scholar
• van Oers JM, Lurkin I, van Exsel AJ, A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005;11:7743-8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hiraishi Y, Wang H, Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 2005;117:166-8
   PubMed Web of Science ®Google Scholar
• Shain S, Saric T, Ke L, Endogenous fibroblast growth factor-1 or fibroblast growth factor-2 modulate prostate cancer cell proliferation. Cell Growth Differ 1996;7:573-86
   PubMedGoogle Scholar
• Saric T, Shain SA. Androgen regulation of prostate cancer cell FGF-1, FGF-2, and FGF-8: preferential down-regulation of FGF-2 transcripts. Growth Factors 1998;16:69-87
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Froum S, Hamby James M, Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998;17:5896-904
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Peng J, Garrett EN, CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91
   PubMed Web of Science ®Google Scholar
• Lee SH, Lopes de Menezes D, Vora J, In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41
   PubMed Web of Science ®Google Scholar
• Bhide RS, Cai Z-W, Zhang Y-Z, Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 nhibitor. J Med Chem 2006;49:2143-6
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21
   PubMed Web of Science ®Google Scholar
• McDermott LA, Simcox M, Higgins B, RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. Bioorg Med Chem 2005;13:4835-41
   PubMedGoogle Scholar